Pompeo Volpe Selected Research

Calsequestrin

1/2020	Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants.
1/2018	Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
2/2014	Post-natal heart adaptation in a knock-in mouse model of calsequestrin 2-linked recessive catecholaminergic polymorphic ventricular tachycardia.
6/2013	Decreased RyR2 refractoriness determines myocardial synchronization of aberrant Ca2+ release in a genetic model of arrhythmia.
8/2008	Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: effects of CASQ2 mutations linked to sudden cardiac death.
7/2008	Catecholaminergic polymorphic ventricular tachycardia-related mutations R33Q and L167H alter calcium sensitivity of human cardiac calsequestrin.
9/2006	Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia.
5/2006	Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death.
3/2004	Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin.
9/2003	Calsequestrin determines the functional size and stability of cardiac intracellular calcium stores: Mechanism for hereditary arrhythmia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pompeo Volpe Research Topics

Disease

13	Polymorphic catecholergic ventricular tachycardia 01/2020 - 03/2004
5	Cardiac Arrhythmias (Arrythmia) 06/2016 - 09/2003
4	Cardiac Sudden Death (Sudden Cardiac Arrest) 08/2013 - 03/2004
2	Atrophy 12/2021 - 01/2013
2	Muscular Atrophy (Muscle Atrophy) 03/2021 - 01/2017
2	Ventricular Tachycardia 01/2018 - 09/2006
2	Sudden Death 03/2004 - 09/2003
1	Atrial Fibrillation 01/2020
1	Fibrosarcoma 01/2017
1	Atrophic Muscular Disorders 01/2017
1	Malignant Hyperthermia 09/2013
1	Muscular Diseases (Myopathy) 09/2013
1	Seizures (Absence Seizure) 09/2013
1	Hypertrophy 07/2013
1	Cardiomegaly (Heart Hypertrophy) 07/2013
1	Tachycardia (Tachyarrhythmias) 09/2006
1	Heart Arrest (Cardiac Arrest) 09/2006
1	Fatigue 03/2006

Drug/Important Bio-Agent (IBA)

10	CalsequestrinIBA 01/2020 - 09/2003
5	Phenobarbital (Luminal)FDA Link 08/2013 - 09/2003
4	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 09/2013 - 05/2006
4	Homer Scaffolding Proteins (Homer 1)IBA 09/2013 - 03/2006
4	CalciumIBA 09/2013 - 09/2003
4	Proteins (Proteins, Gene)FDA Link 09/2013 - 03/2004
3	Protein Isoforms (Isoforms)IBA 12/2021 - 03/2006
3	CatecholaminesIBA 01/2020 - 06/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2021
1	Reactive Nitrogen SpeciesIBA 03/2021
1	Tetrodotoxin (Tetradotoxin)IBA 01/2020
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 01/2018
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2017
1	IgA receptor (protein B)IBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Lipocalin-2IBA 01/2017
1	Protein Kinase C-deltaIBA 01/2017
1	Adrenergic Agents (Adrenergic Drugs)IBA 06/2016
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 07/2013
1	Atrial Natriuretic Factor (ANF)IBA 07/2013
1	MyogeninIBA 01/2013
1	Carrier Proteins (Binding Protein)IBA 08/2008
1	Codon (Codons)IBA 09/2006
1	Calcium-Binding ProteinsIBA 03/2004

Therapy/Procedure

1	Denervation 01/2013